Portfolio company
Abgentis
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
This company develops broad-spectrum antibacterial drugs for pharmaceutical firms to treat acute, chronic, and drug-resistant infections.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Arpida
This company develops antimicrobial drugs and broad-spectrum antibiotics to treat patients with severe bacterial infections requiring hospital treatment.
Adjutecpharma
This company develops antibiotic resistance breakers for healthcare providers to treat patients with life-threatening bacterial infections.
Omnix Medical
This biopharmaceutical company develops novel antibiotic agents for patients suffering from life-threatening, drug-resistant bacterial infections.
Discuva
This biotechnology company develops novel antibiotics to treat multi-drug resistant bacterial infections for pharmaceutical partners and healthcare providers.
Amprologix
This biotechnology company develops novel antibiotics to treat antimicrobial-resistant bacterial infections for patients with conditions including MRSA and related skin and wound infections.
AdjutTec
This pharmaceutical company develops antibiotic resistance breakers to treat patients with multidrug-resistant bacterial and fungal infections.
Acurx Pharmaceuticals
This biopharmaceutical company develops small molecule antibiotics to treat patients with bacterial infections caused by priority pathogens.
Nabriva
This biopharmaceutical company develops and commercialises novel antibiotics for patients with serious infections caused by drug-resistant bacteria.